SCHEMBL15041723

SCHEMBL15041723

O=c1c(-c2c(Cl)cc(S(=O)(=O)c3ccncc3)cc2Cl)cc2cnc(Nc3ccc(C4CCCNC4)cc3)nc2n1CC(F)(F)F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 8/20 0.47
EGFR P00533 5/20 0.47
SRC P12931 3/20 0.42
RIPK2 O43353 3/20 0.40
NOD2 Q9HC29 3/20 0.40
WEE1 P30291 2/20 0.40
ACVR1 Q04771 2/20 0.40
PTK2 Q05397 2/20 0.39
PAK4 O96013 2/20 0.39
PKN1 Q16512 2/20 0.39
ABL1 P00519 2/20 0.38
PDGFRB P09619 2/20 0.38
PDGFRA P16234 2/20 0.38
MAPK14 Q16539 2/20 0.38
KIT P10721 1/20 0.38
PAK3 O75914 1/20 0.37
LIMK1 P53667 1/20 0.37
LIMK2 P53671 1/20 0.37
PAK1 Q13153 1/20 0.37
PAK2 Q13177 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14682050 0.79 FGFR1 (0.58) FGFR1EGFRSRCRIPK2NOD2
SCHEMBL13553906 0.78 PKN1 (0.42) FGFR1EGFRSRCWEE1PTK2
SCHEMBL13553662 0.76 PKN1 (0.47) FGFR1EGFRSRCRIPK2NOD2
SCHEMBL15041462 0.74 CDK4 (0.48) FGFR1EGFRSRC
SCHEMBL15041272 0.74 PKN1 (0.47) FGFR1EGFRSRCWEE1PAK4
SCHEMBL13553543 0.74 PKN1 (0.52) FGFR1EGFRSRCRIPK2NOD2
SCHEMBL13553484 0.74 PKN1 (0.61) FGFR1EGFRRIPK2NOD2WEE1
SCHEMBL15036019 0.73 JAK2 (0.43) FGFR1EGFRWEE1PTK2PAK4
SCHEMBL12807722 0.72 PKN1 (0.57) FGFR1EGFRWEE1PAK4PKN1
SCHEMBL15787974 0.72 WEE1 (0.57) FGFR1EGFRSRCRIPK2NOD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252966-A1 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS AFRAXIS, INC. (US) 2013-09-26 US disclosed
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252966-A1 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS PAK2, PAK6, PAK3 FGFR1 1720/4885EGFR 2713/4885SRC 222/4885
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER PAK5, PAK2, PAK6 FGFR1 1919/4885EGFR 737/4885SRC 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.